ChromaDex Corporation
| NASDAQ: CDXC | Healthcare / Biotechnology / USA |
| 1.46 | 0 | 0.00 | Vol 78.81K | 1Y Perf 18.70% |
| Oct 2nd, 2023 16:00 DELAYED |
| BID | 1.41 | ASK | 1.50 | ||
| Open | 1.44 | Previous Close | 1.46 | ||
| Pre-Market | - | After-Market | 1.48 | ||
| - - | 0.02 1.37% |
| Target Price | 4.84 | Analyst Rating | Strong Buy 1.50 | |
| Potential % | 231.51 | Finscreener Ranking | ★★★★ 52.49 | |
| Insiders Trans % 3/6/12 mo. | -/100/100 | Value Ranking | ★ 39.92 | |
| Insiders Value % 3/6/12 mo. | -/100/100 | Growth Ranking | ★+ 41.48 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 27.78 | Earnings Rating | Strong Buy | |
| Market Cap | 109.55M | Earnings Date | 1st Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.30 | |
| Beta | 1.79 |
Today's Price Range 1.421.48 | 52W Range 1.162.24 | 5 Year PE Ratio Range -27.50-8.10 |
Summary:
Neutral
| Technical Indicators: | Buy |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 2.10% | ||
| 1 Month | -6.41% | ||
| 3 Months | -5.81% | ||
| 6 Months | -3.31% | ||
| 1 Year | 18.70% | ||
| 3 Years | -62.85% | ||
| 5 Years | -65.40% | ||
| 10 Years | -39.17% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -57.09 | |||
ROE last 12 Months | -80.10 | |||
ROA (5Y Avg) | -25.98 | |||
ROA last 12 Months | -42.21 | |||
ROC (5Y Avg) | -71.09 | |||
ROC last 12 Months | -63.70 | |||
Return on invested Capital Q | -3.86 | |||
Return on invested Capital Y | -14.16 | |||
Assets Turnover | 1.10 | |||
Receivables Turnover | 11.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -6.90 | ||||
| 6.80 | ||||
| 2.79 | ||||
| - | ||||
| -9.60 | ||||
| -0.29 | ||||
| 7.04 | ||||
| 0.28 | ||||
| 134.30M | ||||
| Forward PE | -29.19 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.30 | ||||
| 2.30 | ||||
| 0.15 | ||||
| 0.21 | ||||
| -699.20 | ||||
| Leverage Ratio | 2.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 60.50 | ||||
| -29.70 | ||||
| -27.00 | ||||
| -63.30 | ||||
| -29.62 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 51.05M | ||||
| 0.69 | ||||
| 21.73 | ||||
| 26.22 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.04 | -0.03 | 25.00 |
| Q01 2023 | -0.05 | -0.03 | 40.00 |
| Q04 2022 | -0.03 | -0.02 | 33.33 |
| Q03 2022 | -0.06 | -0.04 | 33.33 |
| Q02 2022 | -0.08 | -0.09 | -12.50 |
| Q01 2022 | -0.09 | -0.11 | -22.22 |
| Q04 2021 | -0.11 | -0.08 | 27.27 |
| Q03 2021 | -0.10 | -0.13 | -30.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.03 | 25.00 | Positive |
| 12/2023 QR | -0.03 | 0.00 | - |
| 12/2023 FY | -0.12 | 14.29 | Positive |
| 12/2024 FY | -0.05 | 16.67 | Positive |
| Next Report Date | 1st Nov 2023 |
| Estimated EPS Next Report | -0.03 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 78.81K |
| Shares Outstanding | 75.03K |
| Shares Float | 51.84M |
| Trades Count | 792 |
| Dollar Volume | 114.82K |
| Avg. Volume | 114.41K |
| Avg. Weekly Volume | 146.85K |
| Avg. Monthly Volume | 102.95K |
| Avg. Quarterly Volume | 93.42K |
ChromaDex Corporation (NASDAQ: CDXC) stock closed at 1.46 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 78.81K shares and market capitalization of 109.55M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 110 people. ChromaDex Corporation CEO is Robert N. Fried.
The one-year performance of ChromaDex Corporation stock is 18.7%, while year-to-date (YTD) performance is -13.1%. CDXC stock has a five-year performance of -65.4%. Its 52-week range is between 1.16 and 2.24, which gives CDXC stock a 52-week price range ratio of 27.78%
ChromaDex Corporation currently has a PE ratio of -6.90, a price-to-book (PB) ratio of 6.80, a price-to-sale (PS) ratio of 2.79, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -42.21%, a ROC of -63.70% and a ROE of -80.10%. The company’s profit margin is -29.62%, its EBITDA margin is -27.00%, and its revenue ttm is $51.05 Million , which makes it $0.69 revenue per share.
Of the last four earnings reports from ChromaDex Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.03 for the next earnings report. ChromaDex Corporation’s next earnings report date is 01st Nov 2023.
The consensus rating of Wall Street analysts for ChromaDex Corporation is Strong Buy (1.5), with a target price of $4.84, which is +231.51% compared to the current price. The earnings rating for ChromaDex Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ChromaDex Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ChromaDex Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 46.84, ATR14 : 0.06, CCI20 : -15.48, Chaikin Money Flow : -0.11, MACD : -0.04, Money Flow Index : 49.64, ROC : 4.29, RSI : 49.04, STOCH (14,3) : 68.40, STOCH RSI : 1.00, UO : 55.55, Williams %R : -31.60), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ChromaDex Corporation in the last 12-months were: Frank Jaksch (Buy at a value of $11 830), Fried Robert (Buy at a value of $9 940), Jaksch Frank L Jr (Buy at a value of $11 830), River Ventures Ltd Champion (Buy at a value of $0)
ChromaDex Corporation
ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN nicotinamide riboside, sold directly to consumers as TRU NIAGEN, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
CEO: Robert N. Fried
Telephone: +949.419.0288 ext. 127
Address: 10900 Wilshire Boulevard, Los Angeles 90024, CA, US
Number of employees: 110
